BofA raised the firm’s price target on Bausch + Lomb (BLCO) to $15 from $13 and keeps an Underperform rating on the shares. Bausch + Lomb’s Q4 total revenue beat Street expectations by 2% and the company expects the contact lens market to improve in 2026 to 4.5% growth or better, notes the analyst, who reiterates an Underperform rating given the continued uncertainty around Bausch Health’s (BHC) full separation.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLCO:
- Bausch + Lomb price target raised to $18 from $15 at Deutsche Bank
- Bausch + Lomb price target raised to $16 from $15 at Stifel
- Bausch + Lomb price target raised to $21 from $20 at Citi
- Bausch + Lomb price target raised to $20 from $17 at Barclays
- Maintaining Sell: Structural Overhangs and Margin Shortfalls Overshadow Bausch + Lomb’s Growth Story